{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:25:21Z","timestamp":1785842721555,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K12 HD001259-12"],"award-info":[{"award-number":["K12 HD001259-12"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ygyno.2012.12.022","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T07:55:11Z","timestamp":1355990111000},"page":"22-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"129","author":[{"given":"Edwin A.","family":"Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Rotmensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun C.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Diane","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.12.022_bb0005","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/jnci\/92.11.924","article-title":"Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers","volume":"92","author":"Mutter","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0015","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0002-9440(10)64681-0","article-title":"Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas","volume":"158","author":"Kurose","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0020","first-page":"4569","article-title":"PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells","volume":"61","author":"Zhu","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0025","first-page":"1069","article-title":"Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer","volume":"15","author":"Sakurada","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0030","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-05-2620","article-title":"High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma","volume":"65","author":"Oda","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0035","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2001","journal-title":"J Clin Oncol"},{"issue":"15s","key":"10.1016\/j.ygyno.2012.12.022_bb0040","first-page":"335s","article-title":"Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248","volume":"29","author":"Fleming","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0050","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18S","key":"10.1016\/j.ygyno.2012.12.022_bb9005","article-title":"Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results","volume":"25","author":"Merchan","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2012.12.022_bb9010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin Trials"},{"issue":"suppl","key":"10.1016\/j.ygyno.2012.12.022_bb9015","article-title":"Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer","volume":"30","author":"Einstein","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0060","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0065","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2007.01.019","article-title":"A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study","volume":"105","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0085","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/modpathol.3800579","article-title":"Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha\/VEGF pathway and unfavourable prognosis","volume":"19","author":"Giatromanolaki","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2012.12.022_bb9020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0105","first-page":"5516","article-title":"A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer","author":"Colombo","year":"2007"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0110","article-title":"A randomized phase II (RP2) trial of ridaforolimus (RO) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma","volume":"29","author":"Oza","year":"2001","journal-title":"J Clin Oncol"},{"issue":"s5013","key":"10.1016\/j.ygyno.2012.12.022_bb0115","article-title":"Phase II study of oral ridaforolimus in patients with metastatic and\/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192","volume":"29","author":"Mackay","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.12.022_bb0120","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"issue":"s 5012","key":"10.1016\/j.ygyno.2012.12.022_bb0125","article-title":"A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"29","author":"Slomovitz","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.12.022_bb9025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2012.04.013","article-title":"Cardiovascular disease is the leading cause of death among endometrial cancer patients","volume":"126","author":"Ward","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ygyno.2012.12.022_bb9030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"N\u00e9grier","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2012.12.022_bb9035","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/1078-0432.CCR-11-2488","article-title":"Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438)","volume":"18","author":"Margolin","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ygyno.2012.12.022_bb9040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812009705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812009705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:32:35Z","timestamp":1758771155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812009705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0090825812009705"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.12.022","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969752.793471344","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717969752.793469630","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}